- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Matinas BioPharma Third Quarter 2022 Results Conference Call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded. I would now like to turn the conference over to Dr. Representative BioPharma. Relations Investor Bhargava, for Matinas Ankit

You may begin.

Ankit Bhargava

a everyone. you quarter results for you, we results Dagmar. the along thank afternoon, Company Good issued site section afternoon, the this third accompanying Thank with joining business our And Matinas call. site. release Earlier which release updates. press today’s Web The with conference Web financial XXXX are available of webcast section. Investors available the on the is joining through presentation, Investor the There the BioPharma by Matinas under are BioPharma slides

Speaking Chief Financial Development Chief on Terry Officer; today’s Officer; call Officer; Chief Kucinski, will Keith Officer. be Medical Jerry Matkovits, Chief and Executive Jabbour, Dr. Ferguson, Terry Dr.

questions like expectations Q&A I of call during this These time, We during remind remarks intentions, to uncertainties. At hopes, our beliefs, or involve risks Business have also Thomas answer Hoover, section. would Mr. listeners state and management’s this Chief are made and projections that our may forward-looking the statements future. to Officer, the available

differ this securities call federal the Harbor and to Safe are current based results pursuant Matinas made of expectations actual could on statements BioPharma’s These provisions on forward-looking laws. statements are materially. Forward-looking

reliance result, any you a place undue should not statements. As forward-looking on

documents in section section. of the will BioPharma site. factors Matinas to Some files such the from those with the forward-looking company’s be Investors Web call also results Securities An could contemplated on that of reports Web available are this SEC’s site to the Investors the company’s site of in Exchange the by Web and archive the the posted in statements actual cause differ These Commission. periodic materially are and discussed

for session. will Following open we the remarks, the a company’s question-and-answer call prepared

over to Now I Jerry. turn the will call

Jerry Jabbour

financial time us to you, Thank XXXX quarter highlights recent the third This and we will for Good you today. review and of join our results provide progress. afternoon, morning, everyone, taking thank some our Ankit.

call timing for filing schedule departed our from and this have We normal quarter.

I this So quick providing to thought begin would by some color explain I change.

for lot early morning participate a calls. First, a investors with we there our competition have and time seen to opportunity attention meaningful in investor be way. convenient an to is and valued of able to analysts analyst in We provide wanted a more for that the

the Second, that been Dr. laid I thought Meeting and to returning out until earlier tomorrow trial it Monday, had had not for our to preparation trip stay Matkovits Phase temporarily, travel postponed for of Uganda we planning being fall. we for on XXth. best schedule stockholders and Despite our Annual analysts November our set in X to this

now get So let's into it.

quarter the milestones we and During company. significant our have third for achieved today, through

-- simply unprecedented would of doses oral University are doctors the an that from associated the safe this able Matkovits trial later aggressively Minnesota cryptococcal their goals, for brain, disease next to Phase Dr. our EnACT company We amphotericin, patient been Boulware six will for bit clinical positioned a boxes IV all MATXXXX are results investors to and B with with in X for kidney feedback commitment allowing of to the list of thank to vulnerable detail MATXXXX Dr. KOLs first how we many that in being Phase of EnACT Washington cryptococcal this itself weeks. Uganda trial Week investigators achieve working virtually with entire fantastic, we amphotericin Phase preparing have Overall, that during the survival the was in EnACT in are was in team want population. go set directly in XXXX. patient at proud and more trial. are infectious the commence effective in and quarter important check the meningitis top the never the from Dr. delivered of successful rates on on clinical possible. announcement showing for her very to results clinical We dedicated ID study our two X to for survival therapy meningitis. ago able of and X trial into highly and The our call. staff oral something the a year. of and MATXXXX Phase of of excess XX% the eliminate and closely Matkovits of X At from results trial was we're Cohort to of A thought of historically use David X of up which patients, in prides formulations the accomplish very and to well interim list our weeks be a deliver EnACT we toxicity

data Dr. In crypto, addition to in impressive these

and Mucormycosis. the infection, fungal review Ashraf study on of Week will from its Ibrahim preclinical MATXXXX Harbor-UCLA Center deadly Lundquist presented the Dr. the ID another Institute with Medical data vivo. some in briefly of impact at promising highlights of this Ferguson

across and which also and of global compelling development the feedback for orphan of this with drug time. granting was registration. Phase the advice, in for at generate European come fungal our designation by scientific cryptococcosis. The could EMA we positions development feedback product from to plan overall Positioning a continuing the aligned Agency FDA received data of EMA and quarter, the not invasive MATXXXX During treatment opportune the more Medicines important infections the supported for for form global X,

first making these list with priority the resources observed fungal by It's extended could an list. believe global well kidney fungal followed and diseases difficult report, and its fungal no As tissues one this the for felt part among very many not body drug first prone the success toxic minimal and health you identified threat In directly into leads attention we stays. up mucormycosis the And the the by research important alarming highlighted the exposing guide highest medium. released resistance October, may well Complicating to development. and invasive to despite classifies resistance use and MATXXXX become cryptococcal fungicidal, drug to in to and and levels oral of on six compounded WHO meningitis in among of WHO prolonged pathogens. infection that to toxicity the aware, the Phase high and pathogens With ideal globally. invasive pathogens cryptococcal delivered infected infection priority for groups; preclinical threat therapies, particularly of of in that to infections The to health, the critical, emerging emergence many attributes drug available fungal it's and Despite and so hospital interactions. also list, underrecognized be therapy of this immunocompromised closely data both human fungal continually to treatment, its the blood. growing three fungal is of severe position weeks, many aspergillosis to to brain compelling of on comfortable consistent populations. rates very mortality. cryptococcal reach. without critical has the that's fungal disease it meningitis, with invasive aspergillosis safe The are high rate, resistance, MATXXXX recurrent It's were was to MATXXXX in of to We mucormycosis, rapid tolerated periods agent. battle a MATXXXX generally an rising itself treatment received an Both we and at Organization little reasons to studying for EnACT, in impact World Health priority have profile houses which is weapon priority fungal against in of high it's important positioned no our meningitis. and X an generated The it's in become and effective its critical

to two, opportunity turn effectively, the informs However, which effectively safely in of infection could With call for fungal is over rearview MATXXXX walk fungus, also and data barrier like be eliminate directly safely X this the in toxicity our demonstrate other priority pathogens and could that, X treat confidence to in for that that could mirror, also to program. this LNC high in treat the carry and one, used high meningitis Matinas, platform of and now we blood us successful Phase infected Dr. aspergillosis balance and our not to amphotericin and Matkovits to like success only MATXXXX more presented I'd but our across molecule B is deadly show extremely mucormycosis historic tissues. our positioned EnACT can MATXXXX planned Phase this EnACT brain MATXXXX detail. and to the cryptococcal the the through

Terry Matkovits

the by now meningitis. X announced from Week label is study in in everyone. recently of detail our afternoon, Thanks, XXXX evaluating on design ID into where with nature the unprecedented data and reflective therapy. Infectious with America oral oral survival the this impressive study. the abstract rates one of of believe IDSA investigators the we our interim data X and of the treatment of cohort We since won't I presented X from randomized and Jerry go just principal all were received by from EnACT cryptococcal September is Cohort outstanding of of at of good and the the the Phase Diseases familiar EnACT open sequential MATXXXX data achieved and everyone Cohort Award Society

both X depicts X a Cohort throughout scene from X Cohorts survival MATXXXX with versus data to in and scene time care now standard Slide survival Ultimately, on infectious Turning disease the treatment in this X. amphotericin IV survival. of each At FDA XX MATXXXX of care point is patient standard the care week trial. outperformed population. in EnACT, entire about what and survival doctors with

but survival. primary not be great for confidence mortality will Phase noninferiority key all heading trial provided of was week X or cause where weak our or powered survival into EnACT a with the secondary data of designed XX Importantly, endpoint two deal endpoint these

a antifungal which represents clearance meaningful are rates of threshold in surrogate rate survival. and was therapies. Jerry these EnACT enhanced degree activity, is fungicidal is in The primary the target clearance in oral marker quantitative associated unprecedented fluid. was that activity at prespecified measurement is of of earlier, EFA As use fungal survival. EnACT has is for the ESA, within infection rate and site robust a clinically become X.X, with recognized of The which well endpoint a mentioned cerebrospinal direct early or of all This the survival

ml highlight This the activity clearance at impact challenging beyond in of and pointed having slides of slide, disease noteworthy ESAs and we remarkable one XXX,XXX with patient in reach Cohort quantitative within survival on the period, X time the baseline was Each highlighted doctors. endpoint these These even Several benefit. our a patients Importantly, the as for the high of X antifungal key to fungal arm, cases culture achieved which fungicidal and noteworthy observation design demonstration on X shows activity with two cryptococcal burdens most such potent treatment rates key including upon data primary Overall, per immediate high of next have of screening. design Phase any why in and historically from as cases. not which early a demonstrated X.X the threshold in is EnACT. and Cohorts the effective induction trial, resulted the robust the is out both incremental MATXXXX the during this infectious X, disease, predicated activity believe had our an Cohort the able treatment of MATXXXX study. that MATXXXX drug is high X CFUs antifungal of as

MATXXXX, or Cohort down sterility, of IV of tolerated there patients reminder, completing weeks of the course XX%. infections. cohort and only kidney MATXXXX MATXXXX achieved designed safe electrolyte loading well weeks with including with all abnormalities our even breakthrough X no two, doses two with MATXXXX. As two XX% was In no treatment patients treatment to toxicity a was after amphotericin. and step was as observed therapy survival were additionally induction of six with evaluate

we design success. study X this for reasons. Phase design replicates few degree of We've its cohort this a in there should high and believe Our key chosen confidence be a

primary key a predicated very noninferiority First, standard which XX% our is derisk comfortable margin design a XX% of care, survival with a goal. it's endpoint on at against

going practice, to cryptococcal meningitis in physicians presenting deadly IV patients Secondly, or invasive treating fungal on other most an infections most likely patients start therapy. with are

an next design, treatment And important enrollment could likely of to faster physician this We're guidelines than doses Third, both loading customary, proceed is excited much the with this will IV upon quarter be favorably more study fourth, year. payer likely available. and X MATXXXX included the early for look acceptance. adoption and in faster to initiate first Phase element is

And additional five. study reached important design patient deaths once months XX expand is expected enrollment the up half sites expected unforeseen add XX% drugs. to FDA second unrelated of reviewed data XXXX. aspects line another with will patients our of approximately clinical to is We offset has potential derisked to adaptive the our Enrollment take in to to top

mention Before able I like over Dr. to call manufacturing the the to make MATXXXX. some the on been turn of of I would progress to we've CMC Ferguson, side

you Fisher to MATXXXX. readiness report as we manufacturing we our for Scientific Phase with Thermo to enter Thermo As are am we and transition schedule X. and good partnering proceeding the NDA on a pleased know, to are that external both internal position and in efforts, commercial I Fisher is due for

I for world. our ourselves to will development, ensure turn intent some prospective the program. and Dr. We the Ferguson of successful around over product this call now partners commercialization color are for on MATXXXX our the additional on important and to everything registration within doing control

Terry Ferguson

of Building ideal kidney MATXXXX we same key longer propositions agent power killing of convenient and with off making at term toxicity, is amphotericin fungal avoidance are an Terry. and of of capability and while for the value time important. the as our Thanks, comments, Terry's patients Jerry efficacy of oral it safe significant LNC to incredibly antifungal the administration both and platform preserve B, positioning

meet XXXX. beginning developed FDA and of for are Phase with for protocol broader indication Phase the we've infections discuss While plan study program our X we the meningitis, of with in treatment cryptococcal outline of half to this first the fungal X to the an a for invasive treatment a also

the in pathogens. broadly the Our is as securing fungal WHO drug MATXXXX, maximizing of ultimate orphan this identified be as also treatment for while exclusivities goal multiple positioning indications priority available those used regulatory possible to

leukemia potential continue to immunocompromised invasive and the Underscoring believe in generate transplant prevention patients, in patients infections, of we support are especially Additionally, MATXXXX broader of as has applications we important these for use MATXXXX. of plans patients. potential fungal such data

earlier, As mentioned Jerry Dr.

Ashraf strains for MATXXXX projected is lately, option Kucinski, the in call turn MATXXXX the these seen of the of study MATXXXX deadly MATXXXX in for Overall, have of late Chief clinical Medical Ibrahim who two global MATXXXX this This will demonstrated in program. vivo Harbor-UCLA to our impressive invasive of for in Week. treating data with and well positioned important infections. treatment of potentially the ID Institute our Keith Lundquist different presented Center mucormycosis at breaking efficacy survival deal IV a as results. mucorales that positioning mice, median of space survival invasive time, more of being in immunosuppressed with B, we burden lung and partnership significantly bodes thus comparable success to We've organs, activity the created of US in believe overall enhanced Officer, will target the fungal significant interest ambisome recent global discuss brain, a fungal tissue prolonged including conventional I amphotericin for reduced and MATXXXX our and financial treatment over Financial now value we revenues.

Keith Kucinski

to at projections, from continue current to everyone. good reflected provide million approximately XXXX to loss turn of through for planned decrease Jerry? results along a $XX.X collaboration net from over attributable net that with current concluding shareholders basic loss Today, year hand believe financial million the The third on and of reduced the compared quarter now diluted million, or sufficient is basic diluted and and the $X.X or September a of expenses XX, net XXXX, loss cash million December common were SE a will the company reported on I of during Cash, per resulted marketable slight to approximately $XX.X of in afternoon, which Terry, recording XX, equivalents XXXX. to shareholders million fund at cash $X.XX operating share for research period $X.X loss securities its we its Based same revenue share year-over-year. to Jerry operations XXXX. attributable period pipeline $X.XX Thanks, $X.X updates to compared the some in per the XXXX. and a company back common thoughts. with to and BioNTech call

Jerry Jabbour

want Keith. our update of our know pipeline I did provide I investors to an many on closely. are following Thanks, since these program

learned our collaboration importantly, is few months. licensing and well about technology ongoing. the putting most in make remain over and we lot research the our acids have shareholders these a BioNTech potential and of extremely oral near large best with Happily, discussions term. nucleic our and we for are First nucleic application want to The we and delivery progressing our position its past company and sure long to our both acids is

We studies success are are possible. of Ultimately, for to commence for in as BioNTech with probability studies. overall each these of looking we soon steps both of to vivo are together in the working vitro there lot diligently the And along and increase as way. us, a

license numerous make are right look at in space the the access I our from side, deal see this a third a the deal times also for are to parties. have looking of to On platform. interest favorably fair publicly gratified that prepared and we we precedents and very stated to We for other lot are LNC

on believe continue companies, for this to to BioNTech and a toward deal are end. optimistically prior goal. sense We that working year’s with have makes We both to hope an that update

The to uncertain that in of is we times. to chosen I development other thing judiciously highlight resources want have these down slow MATXXXX to consciously allocate market

Xa for advancing Phase our to MATXXXX first cap options considerable nondilutive efforts into allowing financial and/or value In In our the term, financing to our mature other at provides return materialize our continue drug. our LNC focusing oral in platform potential. want moving with shareholders. continue prior in position enterprise the belief relative into its that some which far the believe we the Unlike push of companies, to to believe strength. study believe the platform X cash, in is potential greatest Phase represents a opportunity our looking picture, on small short to inexpensive for While and we and expansion of and from we we forward aminoglycosides, prioritize market’s biotech overall many of excess we a

to we cash be do multiple we opportunities to term undervalued, cash and us we technology. intelligently into capitalize continue as While short and position able a XXXX products be for nondilutive believe influxes runway advance our to

We resources will of interest. to continue shareholder always our and protect been stewards have our we good

and We thoughtful our And we be achieve boxes checked cash focused intently are of objectives. and of potential the the extend Each market. several will there Overall, key continue happen ways with between several this in XXXX. to should that remaining to viewed be could we would runway. are by could the be shareholders the executing in have we are then on are these one and how of progress year-to-date, be inflection and more beneficially viewed we points, with we value or these now there and our as into term, the which end short made believe year, pleased to

to patent well which and and this we the further us have technology platform LNC partners internally also new used filings, provisional Importantly, we believe portfolio key multiple position our can IP XXXX with surrounding globally. expand with protect

have the of Cell Spring, present the American development at opportunity conference, our given conclude whatever to same delivery and to mRNA-based throughout to We Events want with its our now mRNA such Society Conference will this today. the session. some International multiple both scientific to the doing prepared are taken our and the to lipid drug others as platform it business a engage have Study I will better to the our partnerships issues facilitate operator exposure potentially the Therapeutics most Mycoses and to platform. drug advance today. at BIO-Europe challenging understand them help and awareness Biannual our and our question-and-answer the and of delivery Health year. remarks drug Therapy, control how Group conferences call solve of could within generation Summit, and platform, with the and for capabilities the opportunity turn Gene our next is We increase increase awareness we also over the team to delivery, This time Meeting,

Operator

from [Operator Our Greg Truist. with Fraser question Instructions] first comes

Greg Fraser

Week can asking expand understand XXXX. the universally the that The there the first question clinical for Was at any feedback heard status data you the relapse on were profile? with sterility docs or positive? on better feedback that you the docs like ID the the to from

Jerry Jabbour

I'll Terry, Matkovits he your go Greg, But Dr. turn ahead. over weigh in, if to Dr. thanks that Ferguson. wants to and right for then question.

Terry Matkovits

of So with elements resonated study two of survival the really key was our clinical crypto safety. the and for data our physicians that

been all with resounding far the to what with the an saw supported really have ability really therapies they the was clinical our -- So in exceeded, rates and the seen oral survival available where drug regimen benefit other that has of exceeded setting.

the our Secondly, of drug. profile safety

high treatment So being into product infection. need able B suffering longer invasive patients time a fungal of with patients to first with for a unmet was an of fitting really the treat course from area amphotericin

So and endemic amphotericin invasive the clinically mycoses able to really other drug the our infections, the longer deadly attributes really drug highlighted for has to use those other treatment our for Candida fungal product use such potential of infections, of were expanded is interest. the clinical really use of infections. term be key aspergillosis, the as first for deadly mucor in these expand the And opportunities time an that the

Jerry Jabbour

Ferguson, Terry Terry add Ferguson? else anything there, to

Terry Ferguson

they Just the to with were I that they additional or holes data they think, were questions that that that, add to saw. found not the There very data. in happy

about So they were very excited it.

to the with to And possible were the to do sensed an be general that able without things around of really excitement not during worrying that You presentation. I one it the that of able be taking of Amphotericin was hitherto to about nephrotoxicity. give the I air pictures saw lot think a to slides it people give opportunity orally,

data I excitement, that of with that was saw. the saw sense and the they that very a So happy I lot think

Jerry Jabbour

too. then to trying instead platform me jumped about that mechanism we data is I to understand PK. add that, our encapsulates just right the how. was jumped all one at Greg, to about to about of action most -- the to and mean, talking And the And thing they out of the so themselves, that the it questions And crystal how of activated in how gave drug platform the talk drugs the opportunity a LNC works, cells site this to go infection. access that of and the or us out blood, keeps who solid

So ability I the and with with think, they these that survival therapy so, right were jumped impressed oral platform the an then to a data how, became achieve it moment. to it

And really at people think that that I ID Week the other thing had so happened interested. that's

Greg Fraser

curious I'm with patients like mucor and are you thinking X enrolling Will the duration, you fungal different infections. and invasive aspergillosis, about infections for So size study and Phase about costs? be how also

Jerry Jabbour

in variety who plan I to for from fungal category invasive enroll say, the patients studies. And all or are that. There's would our comer precedent a the basket outline suffering we've protocol for And is this of infections. developed so-called

be that to anything something ones first I meningitis, cryptococcal package and add needs But upon We see to to in on think based endemic have to on think of precedent the and happens submit Matkovits, that a we don't huge patient demonstrated that? maybe mucor will of we to some big and have a We're us mycosis. well prepare FDA numbers obviously in fact the space be Terry the now. you'll those more aspergillosis discussions. working in will it the study success the quarter. But that focus

Terry Matkovits

it hit head. you the on Jerry, think I

So treating would not allow where us do be do we that more would sized then to a infections cryptococcal to design us we intend label do external we've basket demonstrated a in leverage that comparators, study smaller fungal perhaps streamlined for study FDA hope meningitis efficacy significantly to more to a require what with amenable allow vis-a-vis invasive study. to streamlined would open a us to already

Greg Frase

you the formulation the that used use EnACT? you study in in same Can

Terry Matkovits

yes. Correct,

Greg Frase

that possibly study fund you a initiate or own on partner would for to And your it… wait help

Jerry Jabbour

up regulatory have given that trial, cost from perspective, sort and from way we're a global not be from I particularly be in active boxes just we and but mean, this that the beginning that the to the check around board, asset in the able right asset the given setting interest hope the the our this of lot a process, an partner on to of expectation world. would of nature fact a

-- that So would we're third of anticipate we that be is that having part the parties. discussions with

Greg Frase

mucor aspergillosis? ask and get you the more what's with protocol back how long quick remind one queue. I'll treatment But standard ampho just the can one -- us in for and

Jerry Jabbour

It's different, and I'll Matkovits let one. Terry fill that

Terry Matkovits

azole just So because of two use, such complications an these comorbidities, are with that us significant or significant down the amphotericin echinocandins. as toxicities and associated typically those typically followed on to they're drug-drug of one to to it's remind restricted step have to associated that immunocompromised resistance treatment And interactions. use, by have their with IV But with significant of patients weeks and classes underlying anti fungals liabilities polypharmacy.

due really product. amphotericin drug-drug a the with really use to any those drugs treat limitations significant interactions of has that safe to to expand with ability our a drug-drug the positions class alternative and So interaction opportunity to

Operator

question next comes Hazlett Our Robert with from BTIG.

Robert Hazlett

or I've two. Congrats well got one the on progress from as me.

Just acceptance? EU the there? an a additional detail and X, you're EU just the any there bit to work either amenable work in could into make to more wrinkles regard it little to doing or filing Are Phase harmonization go you with of particular

Jerry Jabbour

into to Bert, cryptococcal for of protocol we incorporate were us of meningitis. the was early to one time X overall planning to our going able for get that mean, I the benefits, EMA in it their Phase feedback

of there they want easily. majority the say to which will able would be I to though even are So some that comments aligned, incorporate pretty things see, we their were

criteria, will able this we the meet be use a obviously So both advantage. think to huge agencies, regulatory study is is which that that we a to

ourselves So in to X, of studies of everything align regulatory getting agencies. the because the to can I benefit and then of things other do and position there, think that's feedback, having the being or that smaller Phase find and at Dr. appease we start not proactive Matkovits going

Robert Hazlett

regard and might are seems about deals XXXX more just to what of of is active the where license you love I’d talked slice or something that But you be the then this bit types being you'd I like considering. and in And But out, there's of might to with little different process And it carve know status just this is a that there. maybe a get consider an might whole your something to given you ways like to this. look where a of deal sense place, alignment XXXX. in the thing? geographic bit to be little more good

Jerry Jabbour

half, in ID last it's this these good timing their of parties only Cohort particularly for of infections, the have is saw question. who attention this immunocompromised have over In there fact, I the just during and the patients. been now at really development. the We've following brought been the year Bert, ability particularly this interest and X where the call obviously, immunocompromised think treat effectively drug But a business, World that's Health additional patients. it's And time, So Week, some for in by increased the pandemic, the seen, prevalence the time the development increase you with first fungal a by cryptococcus data the Organization's of actively was to therapy everything. piqued also

in precedent regional things this basis. in deals the storm. There's are space. space recently for look in lot years at done can it's FXG you mean, last of couple So I Sidara a at least like pretty a that on a of that or perfect

we think better have a I product.

more product ability think these broader spectrum a have I treat the has effectively pathogens. to a and we has that

So possibility deal open the regional that the know train this indications. we're down that there's deals licensing it. about we going is to and we but We would and not global be and attention. the But populations discounted of stack a well slow is not interest works to that have given here to drug sort What really smart we emergence increasing. these want we has because are patient have opportunity to in the a

about a we supporting can and stand behind lot meningitis smart patient going patient. costs NIH’s we that how fund. reason big a be again, being That focused is support in cryptococcal the we're to the The So execution. of on of they're why Phase study. We're X firmly

others know Terry Hoover us. inform a Matkovits partners. Tom hard that's big variable and working are for to So and I

active have We open. data room that's an

be opportunistic. next be partner comprehensive we So interested business will over would in We say, objective, that of want right key But parties. is of our to finding part the two a canvassing terms I quarters. all

Robert Hazlett

on any able with call, conference order a that same to following broader don't I'm just be topic being particular negotiate regard considered that's to And BioNTech. but exact any ask Certainly, time, quarterly the affect if to want interested there's particular the in on transaction at to or there? hurdle

Jerry Jabbour

transaction? Bert, in which

Robert Hazlett

BioNTech? deal A for potential broader

Jerry Jabbour

obstacle. it's I don't think an

them that for a consider. of they think there's I things number need to

about value. The I are parties of think And has that how the collaboration a intention they're know directions. number happy all quite we talking pulled different going. with their research is been in

comfortable the But our months think everything deal. things your And so on we timeline, discussions. and I head puts complicated. pleasant exclusivity like have anytime I us oral get are, a two had mature, shareholders are in we have always RNA, to we it. But you're wrap have an in that sense think things ago, would which opportunity urgency around the deal the position things a these and valuations I for would we the right do. messenger of done right think, and proceeding for like trying We If

moving a we're think, t’s cross just it and think able closer every being I sense. to parties i’s. believe question the dot And those It's I both makes of day.

Operator

Securities. Our Riley comes from B. Mamtani Mayank next question from

Sahil Kazmi

all this And and on update, comprehensive progress. interesting on really Congrats the of for thanks Mayank. This Kazmi is EnACT. the Sahil seeing some we're for data from

how So significant of one starting consolidation maybe week as think that study. maybe loading treatment just Could arms and for about in induction context terms about the talk dose care, the amphotericin put versus of expectations your there, of different X in of Phase some is? you you the standard

Jerry Jabbour

there. as doses. of one loading be going for at a as least arms. to sort Phase of X, that walk about talking So back the two We're a far need There's couple MATXXXX things, we loading to week the not dose

day days, XX-day actually receive loading first two MATXXXX a will the period. on over will for to two and transition then So dose it of patients induction balance the oral the

seven by care will the standard of followed where getting of they arm in only amphotericin it's IV So days be fluconazole.

X we of responsible So in effect we antifungal for not Cohort our X is both that saw, what and expect in Cohort don't and was validated the was loading the drug. dose

at gone think benefits it an what is way all dose? very regimen you away having not the physicians just that about Cohort the oral X and I think of the asked I beginning. and for stopped the of takes of to mind the piece Cohort the X, that's loading benefit at question of it's one

I this big about that there's treatment and But treatment to FDA patients be guideline Terry, data is strongest there's file there. two approximately impact indication, to either MATXXXX talk arms. the benefit the the weeks do Terry it the a But us, arms. that some is be for that enrollment think the six of crypto is the think I'll I And XXX what doing specifically randomized you and let to talk want for of two going on way. I to that two crypto essentially study. treatment mean, treatment at believe to It'll Matkovits difference about opportunity what weeks? the we or gave look and maybe one

Terry Ferguson

collaboratively the the a to our did stepping week down of two we design Phase comparison design of we us any way be time same amphotericin cause will of the FDA, treatment registration worked And and replicating the indication mentioned we standard study, for care, focused performed the for that which which Cohort endpoint design it's to the will to trial. was amphotericin X use identically X Phase call, for the expands which that our the in in better our primary X, positioned, is saw what mortality, treatment the than Cohort potentially our data, really product arm. MATXXXX in as during days all allow discussed the final in specifically so week on that So will get first six a are with tested two be the as is of we And X IV Jerry period.

for So in given And cohorts to success we believe independent to able we of noninferiority. been recall have analysis of two that of overall demonstrate be care. statistical that now EnACT we much one will that numerically are the positioned very better survival standard relative

is much noninferior to endpoint, a a bar regulatory are we It's So lower demonstrate we also a from not care. need standard of superiority which to that perspective.

indication benefit a XX% Secondly, saw all based cause week the that that will the where X had of we be we all endpoint again, there be ever This of survival term in support the Cohort longer numerical XX in will replicated indications XX% product. also for standard mortality standard versus on will data, this care, any relative the amphotericin drug regimen. our the And first X key endpoint oral was of care our of survival Cohort to treatment arm.

treatment both week that to success well be label final well very criteria of for the to meet So are throughout positioned we will as pre-specified study able six as we induction -- that for as the label. the believe really the be

Jerry Jabbour

primarily too. to of to year were efficacy, the having weeks. generate six And that getting than aspergillosis our in follow-up agree treatment open able is addition I multiple a be on of they up sets for just And interactions them of in because treatment up that the are of weeks. periods FDA saw you of because also two the treatment safety past whose the mean, benefits that's indication to one the to this that, that's mucormycosis data to that's and that longer what to we of with longer

be that thinking about to longer the trial favorably challenging with factor well. very in how invasive the of should from see to crypto less a streamlined able we're possibility data fungal will as So the for FDA the and indications infections

Sahil Kazmi

more just features preclinical of some the then a the you're might brief informative you collaboration. attractive to discuss that on deploy of platform research And a maybe of and you of thinking models look here? diligence Are have able little been of BioNTech in to question the kind some the ongoing the detail as

Jerry Jabbour

then to we with can't. their and format. with unique coming Yes, or in acids ability RNA things have like go into is -- formulate to two we're two messenger unique strength create really exact novel our or mean, we really the at But who nucleic this I and can't us not and that. together expertise the targets parties liberty areas, formulations

had on challenges had understanding two to to used learning what vivo them lot be in us we go on cell uptake, -- with cell they that terms that So groups deliver, there in of work they position into. a did be lot and between what ran a vitro able to before was also then the the basic of how best to are to of stuff, identify in then to study. identification, what going And

back and the building long I collaborative forth. really go term. from has and but for can't Other it into many been that, the was So foundation it than details, it

why And sense to two so the I long for the together makes term. think of learned work about it us both parties deal great for have a

Operator

[Coffield]. from Our next comes Matthew question

Unidentified Analyst

LNC congrats guys progress. Thanks on and continued the

step therapy. and So CM the in developments of your of expansion? success based What how XXXX are benefits treatment usage and ultimately future that pivotal on on you focused the terms a focus Cohort relevant therapy and down see frontline on as X been thoughts on in platform

Jerry Jabbour

from do about good have open issues. and get have had It's ourselves big questions the after And obviously step We to are physicians’ X, account the taking transitioning may just how be. prescription down Cohort work is question patients’ showing time. oral enrolling get starting things at in that obviously days checked prescription therapy studies practice about they minds us also But factor is our to these this to lot it's It to place versus at out as it's question, we to a the looked And like. a survival with we you keep really treatment get IV MATXXXX get Cohort our can of at coming and show a fear but will this that that. you landscape us what able giving It because those allows X all opportunity therapy it. label benefit only obviously design oral as survival starting that the this sort practice. survival, We've there's using success. step trial, if up the through MATXXXX allows going much for you physicians in talking and couldn't and we of And just Why the us the able been of all you're of significantly. an to down to align enhance longer, what Phase of and there to beauty allows reward therapy, every X we derisk the you not necessarily study drug show talk lot studies XX MATXXXX the with weeks XX taking good is that to for can And be can like positioning longer view physician same that we how safely no look there's it boxes. Cohort are pretty of it's where think a and into and data about it think we reality X in payers with gone -- study. We faster, data eliminates of not gain some to over we back the a we've and a to investors. in use week you're understanding

of to And the because length in the ability to the infection the going days. time is in for drug from readmission. [indiscernible] study today, the in just you we're perspective, patient nature your and more They the be of the economic makes are two than show health fungal so with crypto may up Uganda, measure both not we're location to be patients the going which comfortably to able economic than more a out be azoles relapse the show in likely study the And invasive a on prone of that a that to hospital faster. and see resistance be design going cause getting health or aspect hospital and going to there's to that of

going are going us, we better we're study faster be balance patients’ and get to get to and be So it much quicker. on in for think the that the done able hands to economics

Operator

Jerry it turn remarks. for to back will over closing I Now

Jerry Jabbour

see appreciate forward Great, analysts, our thing. taking online participation We and a our judging this your feedback. better I think everyone this look Dagmar. opportunity thank investors and join to the to and I'm to today We you think And able the if afternoon the good for calling today. is works cue slot analysts in by I

keeping We apprised our you thank We're look close we to strong. for support. going for as forward So to you 'XX. to of your progress the balance

the is company our we have biotech benefits of a the One as base. small strength of investor

check closely. on to in the the boxes of We continue work have and for Thanks, to base year and your a XXXX. very us passionate who hard rest going follows We're behalf everybody. informed investor those

Operator

your Thank you. you call. participation. This for concludes today's We conference thank

this day. may great a your at You and lines have time, disconnect

Matinas BioPharma (MTNB) 3 Nov 222022 Q3 Earnings call transcript